Semax Selank and antidepressants have not been tested together in a published human interaction trial. That leaves the combination's risks uncertain, even if someone online says it went well. A prescriber needs the exact medicines and treatment history to assess the proposed pairing.

Semax and Selank are peptides, short chains of protein building blocks. Studies of either peptide alone don't establish what happens when both are added to an antidepressant. Missing reports of trouble aren't the same as a study looking for it.

Semax Selank and antidepressants: what was actually tested?

There are three different kinds of information here. A human combination study can describe what happened with specific medicines. An animal experiment can suggest a biological explanation. An unanswered question remains unanswered, however plausible the explanation sounds.

The often-cited Zozulia study from 2008 enrolled 62 people with persistent anxiety or nervous exhaustion. Published in the S.S. Korsakov Journal of Neurology and Psychiatry, it compared 30 receiving Selank with 32 receiving medazepam. Medazepam is a benzodiazepine, a type of anti-anxiety medicine. It isn't an antidepressant, and the comparison wasn't a study of taking both medicines together.

A 2015 study by Medvedev and colleagues in the same journal did examine a combination. Forty people received Selank with phenazepam; 30 received phenazepam alone. Phenazepam is another benzodiazepine. Researchers reported milder unwanted effects with the combination, including less impairment of attention and memory.

That is human evidence about one particular pairing. It doesn't establish compatibility with an antidepressant or with Semax added. Neither study tested Semax and Selank together alongside an antidepressant.

Why the fluvoxamine rat study doesn't answer the question

A Glazova study in Neuropeptides, 2021 can sound relevant because its title names Semax and an antidepressant. The order of treatment changes its meaning.

Rat pups received fluvoxamine during days 1–14 after birth. Semax treatment followed during days 15–28. Researchers later examined behavior and brain chemistry. They reported changes in learning, anxiety-like behavior and chemical measurements after that early exposure.

This was a study of developing rats given the two treatments in sequence. It wasn't a trial of adults taking an antidepressant and Semax together. It also didn't include Selank.

Fluvoxamine and fluoxetine are different medicines. A fluvoxamine experiment cannot answer a question about Semax with fluoxetine, and it supplies no human interaction estimate for sertraline. Shared drug families don't make those substitutions valid.

Serotonin concerns: a mechanism isn't an interaction rate

Serotonin is a chemical that carries messages between nerve cells. SSRIs, short for selective serotonin reuptake inhibitors, are antidepressants that keep it available longer. Fluoxetine and sertraline are examples.

There are reasons to investigate possible overlap. A 2005 rodent study in Neurochemical Research found that Semax raised a serotonin-breakdown marker in part of the brain. A 2009 rat study in Experimental and Clinical Pharmacology examined Selank after researchers had blocked serotonin production. It found changes in how serotonin was processed in part of the brain.

Neither finding shows how the combined peptides affect a person's antidepressant treatment. They don't establish that serotonin rises predictably in people, or that a particular combination causes a particular reaction.

Serotonin syndrome is a potentially life-threatening reaction involving excessive serotonin activity. The peptide studies cannot establish or rule out that risk for this combination, or provide a reliable rate. MedlinePlus lists signs such as agitation or restlessness, hallucinations, a fast heartbeat, high blood pressure, a raised temperature, overactive reflexes, loss of coordination, nausea, vomiting and diarrhea, usually within minutes to hours, and advises contacting a provider right away; untreated, the reaction can be deadly. A symptom list cannot diagnose the cause.

The separate guides to Semax side effects and Selank side effects cover their broader safety records. Adding the two records together doesn't create a safety study of the pair.

What a prescriber checks in the medication list

Medication reconciliation means building one accurate list of everything a person uses. For an antidepressant interaction question, that includes the exact medicine, amount, timing and recent changes. Pharmacy records and medication labels help resolve differences between lists.

The review includes other prescriptions, occasional medicines, supplements and alcohol. A cough medicine or another mental-health prescription can matter even when the reader thinks of only one daily antidepressant. MedlinePlus's antidepressant guide explains why the whole list matters and why treatment changes belong with the treating clinician. Our Semax/Selank and Adderall guide covers the separate stimulant-interaction evidence and its limits.

Timing alone doesn't settle the question. FDA's Semax evidence review found no human studies tracking how Semax enters and leaves the body. There is no validated spacing interval that establishes compatibility between this pair and an antidepressant.

The prescriber also reviews existing symptoms and who manages the antidepressant. New sleep trouble or agitation needs a clinical assessment of possible causes. It cannot automatically be assigned to a peptide, a drug interaction or the underlying condition. The Semax/Selank visit questions cover the wider intake.

What the recent HHS policy changes in this discussion

Compounding means preparing a medication for an individual prescription. As of November 5, 2026, the day this article was written, an October 30 HHS notice announces a draft peptide-compounding policy. Its six-peptide list names Semax, not Selank; the full policy explainer covers all ten conditions.

An enforcement policy does not establish antidepressant compatibility.

What the prescription review can settle

A clinical review can assess whether the proposed preparation fits a person's history and current treatment. It can identify known concerns in the existing medication list and set a follow-up plan. It cannot turn missing interaction evidence into a guarantee.

Semax/Selank prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. If prescribed, a licensed U.S. compounding pharmacy prepares and dispenses the medication. The prescriber sets any dose and follow-up plan. Considering a peptide is not a reason to independently stop or reduce existing antidepressant treatment.